World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
50873
World Ranking
5294
National Ranking
2861

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Mark J. Ratain is affiliated with the University of Chicago in the United States. Their research focuses primarily within the field of Medicine, with particular emphasis on Oncology, Economics and Econometrics, Pharmacology, Molecular Biology, and Pulmonary and Respiratory Medicine.

The scientist's work covers a range of topics including Health Systems, Economic Evaluations, Quality of Life; Pharmacogenetics and Drug Metabolism; Colorectal Cancer Treatments and Studies; Economic and Financial Impacts of Cancer; Statistical Methods in Clinical Trials; Cancer Genomics and Diagnostics; and Chronic Lymphocytic Leukemia Research.

Frequent publication venues for their research include:

  • UNC Libraries
  • Clinical Pharmacology & Therapeutics
  • Journal of Clinical Oncology
  • The Journal of Clinical Pharmacology
  • JAMA Oncology

Recent papers authored or co-authored by Mark J. Ratain encompass a variety of clinical and pharmacological themes, such as:

  • "COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia" (2020, Clinical Pharmacology & Therapeutics)
  • "Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value" (2020, Clinical Pharmacology & Therapeutics)
  • "Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments" (2021, Journal of Clinical Oncology)
  • "Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19" (2020, JAMA Oncology)
  • "Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy" (2020, Clinical Pharmacology & Therapeutics)

Co-authors frequently collaborating with Mark J. Ratain include:

  • Garth W. Strohbehn
  • Kouros Owzar
  • Peter H. O'Donnell
  • Keith Danahey
  • Daniel A. Goldstein

The scientist has also been recognized as a member of the Association of American Physicians.

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Tumour heterogeneity in the clinic

    Philippe L. Bedard;Aaron R. Hansen;Aaron R. Hansen;Mark J. Ratain;Lillian L. Siu;Lillian L. Siu

  • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

    Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen

  • Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

    Lalitha Iyer;Christopher D. King;Peter F. Whitington;Mitchell D. Green

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

    T Eisen;T Ahmad;K T Flaherty;M Gore

  • Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

    Jonas A. de Souza;Bonnie J. Yap;Kristen Wroblewski;Victoria Blinder

  • Perceptions of cancer patients and their physicians involved in phase I trials.

    Christopher Daugherty;Mark J. Ratain;Eugene Grochowski;Carol Stocking

  • Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea

    Elora Gupta;Timothy M. Lestingi;Rosemarie Mick;Jacqueline Ramirez

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • The development of a financial toxicity patient-reported outcome in cancer: The COST measure.

    Jonas A. de Souza;Bonnie J. Yap;Fay J. Hlubocky;Kristen Wroblewski

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

    Lalitha Iyer;Diana Hall;Soma Das;Melissa A. Mortell

  • Oral chemotherapy: rationale and future directions.

    Mark D. DeMario;Mark J. Ratain

  • Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.

    MJ Ratain;LS Kaminer;JD Bitran;RA Larson

  • Pharmacokinetic variability of anticancer agents

    Samir D. Undevia;Gonzalo Gomez-Abuin;Mark J. Ratain

  • Pharmacogenomics: Challenges and Opportunities

    Dan M. Roden;Russ B. Altman;Neal L. Benowitz;David A. Flockhart

  • Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.

    H M Golomb;A Jacobs;A Fefer;H Ozer

  • The Development of a Financial Toxicity Patient-Reported Outcome in Cancer

    Jonas A. de Souza;Bonnie J. Yap;Fay J. Hlubocky;Kristen Wroblewski

Frequent Co-Authors

Richard L. Schilsky
Richard L. Schilsky University of Chicago
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Everett E. Vokes
Everett E. Vokes University of Chicago
Theodore Karrison
Theodore Karrison University of Chicago
Walter M. Stadler
Walter M. Stadler University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Gini F. Fleming
Gini F. Fleming University of Chicago
Rosemarie Mick
Rosemarie Mick University of Pennsylvania
Soma Das
Soma Das University of Chicago
Harvey M. Golomb
Harvey M. Golomb University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine can open doors to a variety of related healthcare fields. For those seeking flexibility and affordability, online programs are an excellent option. Many students start their journey with nursing, exploring what is the cheapest online college for nursing? to help minimize debt while gaining essential qualifications.

As you progress, you may look at advancing your career by becoming a nurse practitioner. Today’s affordable online FNP programs allow working professionals to upskill from home, preparing for more specialized, in-demand roles.

Many registered nurses choose to further their education through the cheapest RN to BSN programs, which expand career options and earning potential. For those passionate about academic research or leadership, online PhD nursing programs offer a pathway to the highest levels in healthcare education and practice.

Exploring these online pathways can help you build a rewarding medical career, tailored to your interests, ambitions, and budget.

Best Scientists Citing Mark J. Ratain

Trending Scientists